ID   KPCD2_HUMAN             Reviewed;         878 AA.
AC   Q9BZL6; M0R2R2; Q8NCK8; Q8TB08; Q9P0T6; Q9Y3X8;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=Serine/threonine-protein kinase D2;
DE            EC=2.7.11.13;
DE   AltName: Full=nPKC-D2;
GN   Name=PRKD2; Synonyms=PKD2; ORFNames=HSPC187;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION AT SER-876,
RP   AND VARIANT ALA-835.
RC   TISSUE=Pancreas;
RX   PubMed=11062248; DOI=10.1074/jbc.M008719200;
RA   Sturany S., Van Lint J., Mueller F., Wilda M., Hameister H.,
RA   Hoecker M., Brey A., Gern U., Vandenheede J., Gress T., Adler G.,
RA   Seufferlein T.;
RT   "Molecular cloning and characterization of the human protein kinase
RT   D2. A novel member of the protein kinase d family of serine threonine
RT   kinases.";
RL   J. Biol. Chem. 276:3310-3318(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ALA-835.
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 337-878 (ISOFORM 1/2), AND
RP   VARIANT ALA-835.
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 574-878 (ISOFORM 1/2), AND
RP   VARIANT ALA-835.
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [6]
RP   ENZYME REGULATION, AND PHOSPHORYLATION AT SER-706; SER-710 AND
RP   SER-876.
RX   PubMed=12058027; DOI=10.1074/jbc.M200934200;
RA   Sturany S., Van Lint J., Gilchrist A., Vandenheede J.R., Adler G.,
RA   Seufferlein T.;
RT   "Mechanism of activation of protein kinase D2(PKD2) by the
RT   CCK(B)/gastrin receptor.";
RL   J. Biol. Chem. 277:29431-29436(2002).
RN   [7]
RP   FUNCTION IN NF-KAPPA-B ACTIVATION, PHOSPHORYLATION AT TYR-438, AND
RP   MUTAGENESIS OF TYR-438.
RX   PubMed=15604256; DOI=10.1158/0008-5472.CAN-04-0981;
RA   Mihailovic T., Marx M., Auer A., Van Lint J., Schmid M., Weber C.,
RA   Seufferlein T.;
RT   "Protein kinase D2 mediates activation of nuclear factor kappaB by
RT   Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells.";
RL   Cancer Res. 64:8939-8944(2004).
RN   [8]
RP   FUNCTION IN TRAFFICKING.
RX   PubMed=14743217; DOI=10.1038/ncb1090;
RA   Yeaman C., Ayala M.I., Wright J.R., Bard F., Bossard C., Ang A.,
RA   Maeda Y., Seufferlein T., Mellman I., Nelson W.J., Malhotra V.;
RT   "Protein kinase D regulates basolateral membrane protein exit from
RT   trans-Golgi network.";
RL   Nat. Cell Biol. 6:106-112(2004).
RN   [9]
RP   FUNCTION IN ADAPTIVE IMMUNE RESPONSE.
RX   PubMed=17077180; DOI=10.1093/intimm/dxl108;
RA   Irie A., Harada K., Tsukamoto H., Kim J.R., Araki N., Nishimura Y.;
RT   "Protein kinase D2 contributes to either IL-2 promoter regulation or
RT   induction of cell death upon TCR stimulation depending on its activity
RT   in Jurkat cells.";
RL   Int. Immunol. 18:1737-1747(2006).
RN   [10]
RP   FUNCTION.
RX   PubMed=16928771; DOI=10.1152/ajpcell.00308.2006;
RA   Chiu T.T., Leung W.Y., Moyer M.P., Strieter R.M., Rozengurt E.;
RT   "Protein kinase D2 mediates lysophosphatidic acid-induced interleukin
RT   8 production in nontransformed human colonic epithelial cells through
RT   NF-kappaB.";
RL   Am. J. Physiol. 292:C767-C777(2007).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC7, ENZYME REGULATION, SUBCELLULAR
RP   LOCATION, AND PHOSPHORYLATION AT SER-244.
RX   PubMed=17962809; DOI=10.1038/sj.emboj.7601891;
RA   von Blume J., Knippschild U., Dequiedt F., Giamas G., Beck A.,
RA   Auer A., Van Lint J., Adler G., Seufferlein T.;
RT   "Phosphorylation at Ser244 by CK1 determines nuclear localization and
RT   substrate targeting of PKD2.";
RL   EMBO J. 26:4619-4633(2007).
RN   [12]
RP   FUNCTION IN CELL ADHESION.
RX   PubMed=17951978; DOI=10.1254/jphs.FP0070858;
RA   Ge X., Low B., Liang M., Fu J.;
RT   "Angiotensin II directly triggers endothelial exocytosis via protein
RT   kinase C-dependent protein kinase D2 activation.";
RL   J. Pharmacol. Sci. 105:168-176(2007).
RN   [13]
RP   PHORBOL-ESTER BINDING, AND MUTAGENESIS OF PRO-275.
RX   PubMed=18076381; DOI=10.1042/BJ20071334;
RA   Chen J., Deng F., Li J., Wang Q.J.;
RT   "Selective binding of phorbol esters and diacylglycerol by individual
RT   C1 domains of the PKD family.";
RL   Biochem. J. 411:333-342(2008).
RN   [14]
RP   FUNCTION IN SECRETORY PATHWAY, AND SUBCELLULAR LOCATION.
RX   PubMed=18262756; DOI=10.1016/j.cellsig.2008.01.003;
RA   von Wichert G., Edenfeld T., von Blume J., Krisp H., Krndija D.,
RA   Schmid H., Oswald F., Lother U., Walther P., Adler G., Seufferlein T.;
RT   "Protein kinase D2 regulates chromogranin A secretion in human BON
RT   neuroendocrine tumour cells.";
RL   Cell. Signal. 20:925-934(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-710 AND SER-876, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-200; SER-203; SER-206;
RP   SER-214 AND SER-710, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH LCK.
RX   PubMed=19192391; DOI=10.5483/BMBRep.2009.42.1.035;
RA   Li Q., Sun X., Wu J., Lin Z., Luo Y.;
RT   "PKD2 interacts with Lck and regulates NFAT activity in T cells.";
RL   BMB Rep. 42:35-40(2009).
RN   [19]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=19001381; DOI=10.1074/jbc.M807546200;
RA   Hao Q., Wang L., Zhao Z.J., Tang H.;
RT   "Identification of protein kinase D2 as a pivotal regulator of
RT   endothelial cell proliferation, migration, and angiogenesis.";
RL   J. Biol. Chem. 284:799-806(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206; SER-518; SER-710;
RP   TYR-717 AND SER-876, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; SER-198; SER-200;
RP   SER-203; SER-206 AND SER-710, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   FUNCTION, INTERACTION WITH CIB1 ISOFORM 2, AND MUTAGENESIS OF SER-244;
RP   ASP-695; SER-706 AND SER-710.
RX   PubMed=23503467; DOI=10.1038/onc.2013.43;
RA   Armacki M., Joodi G., Nimmagadda S.C., de Kimpe L., Pusapati G.V.,
RA   Vandoninck S., Van Lint J., Illing A., Seufferlein T.;
RT   "A novel splice variant of calcium and integrin-binding protein 1
RT   mediates protein kinase D2-stimulated tumour growth by regulating
RT   angiogenesis.";
RL   Oncogene 33:1167-1180(2014).
RN   [28]
RP   STRUCTURE BY NMR OF 395-509.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the PH domain of protein kinase C, D2 type from
RT   human.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 526-534.
RX   PubMed=18836451; DOI=10.1038/ni.1660;
RA   Mohammed F., Cobbold M., Zarling A.L., Salim M., Barrett-Wilt G.A.,
RA   Shabanowitz J., Hunt D.F., Engelhard V.H., Willcox B.E.;
RT   "Phosphorylation-dependent interaction between antigenic peptides and
RT   MHC class I: a molecular basis for the presentation of transformed
RT   self.";
RL   Nat. Immunol. 9:1236-1243(2008).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-324; VAL-496; GLY-604; ARG-773;
RP   GLU-848 AND GLU-870.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that converts transient
CC       diacylglycerol (DAG) signals into prolonged physiological effects
CC       downstream of PKC, and is involved in the regulation of cell
CC       proliferation via MAPK1/3 (ERK1/2) signaling, oxidative stress-
CC       induced NF-kappa-B activation, inhibition of HDAC7 transcriptional
CC       repression, signaling downstream of T-cell antigen receptor (TCR)
CC       and cytokine production, and plays a role in Golgi membrane
CC       trafficking, angiogenesis, secretory granule release and cell
CC       adhesion. May potentiate mitogenesis induced by the neuropeptide
CC       bombesin by mediating an increase in the duration of MAPK1/3
CC       (ERK1/2) signaling, which leads to accumulation of immediate-early
CC       gene products including FOS that stimulate cell cycle progression.
CC       In response to oxidative stress, is phosphorylated at Tyr-438 by
CC       ABL1, which leads to the activation of PRKD2 without increasing
CC       its catalytic activity, and mediates activation of NF-kappa-B. In
CC       response to the activation of the gastrin receptor CCKBR, is
CC       phosphorylated at Ser-244 by CSNK1D and CSNK1E, translocates to
CC       the nucleus, phosphorylates HDAC7, leading to nuclear export of
CC       HDAC7 and inhibition of HDAC7 transcriptional repression of
CC       NR4A1/NUR77. Upon TCR stimulation, is activated independently of
CC       ZAP70, translocates from the cytoplasm to the nucleus and is
CC       required for interleukin-2 (IL2) promoter up-regulation. During
CC       adaptive immune responses, is required in peripheral T-lymphocytes
CC       for the production of the effector cytokines IL2 and IFNG after
CC       TCR engagement and for optimal induction of antibody responses to
CC       antigens. In epithelial cells stimulated with lysophosphatidic
CC       acid (LPA), is activated through a PKC-dependent pathway and
CC       mediates LPA-stimulated interleukin-8 (IL8) secretion via a NF-
CC       kappa-B-dependent pathway. During TCR-induced T-cell activation,
CC       interacts with and is activated by the tyrosine kinase LCK, which
CC       results in the activation of the NFAT transcription factors. In
CC       the trans-Golgi network (TGN), regulates the fission of transport
CC       vesicles that are on their way to the plasma membrane and in
CC       polarized cells is involved in the transport of proteins from the
CC       TGN to the basolateral membrane. Plays an important role in
CC       endothelial cell proliferation and migration prior to
CC       angiogenesis, partly through modulation of the expression of
CC       KDR/VEGFR2 and FGFR1, two key growth factor receptors involved in
CC       angiogenesis. In secretory pathway, is required for the release of
CC       chromogranin-A (CHGA)-containing secretory granules from the TGN.
CC       Downstream of PRKCA, plays important roles in angiotensin-2-
CC       induced monocyte adhesion to endothelial cells. Plays a regulatory
CC       role in angiogenesis and tumor growth by phosphorylating a
CC       downstream mediator CIB1 isoform 2, resulting in vascular
CC       endothelial growth factor A (VEGFA) secretion.
CC       {ECO:0000269|PubMed:14743217, ECO:0000269|PubMed:15604256,
CC       ECO:0000269|PubMed:16928771, ECO:0000269|PubMed:17077180,
CC       ECO:0000269|PubMed:17951978, ECO:0000269|PubMed:17962809,
CC       ECO:0000269|PubMed:18262756, ECO:0000269|PubMed:19001381,
CC       ECO:0000269|PubMed:19192391, ECO:0000269|PubMed:23503467}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activated by DAG and phorbol esters. Phorbol-
CC       ester/DAG-type domains bind DAG, mediating translocation to
CC       membranes. Autophosphorylation of Ser-710 and phosphorylation of
CC       Ser-706 by PKC relieves auto-inhibition by the PH domain.
CC       {ECO:0000269|PubMed:12058027, ECO:0000269|PubMed:17962809}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with LCK. Interacts (via N-
CC       terminal AP-rich region) with CIB1 isoform 2.
CC       {ECO:0000269|PubMed:19192391, ECO:0000269|PubMed:23503467}.
CC   -!- INTERACTION:
CC       Q8WUI4:HDAC7; NbExp=6; IntAct=EBI-1384325, EBI-1048378;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17962809}.
CC       Cell membrane {ECO:0000250|UniProtKB:Q15139}. Nucleus
CC       {ECO:0000269|PubMed:17962809}. Golgi apparatus, trans-Golgi
CC       network {ECO:0000269|PubMed:18262756}. Note=Translocation to the
CC       cell membrane is required for kinase activation. Accumulates in
CC       the nucleus upon CK1-mediated phosphorylation after activation of
CC       G-protein-coupled receptors. Nuclear accumulation is regulated by
CC       blocking nuclear export of active PRKD2 rather than by increasing
CC       import. {ECO:0000269|PubMed:17962809}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BZL6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BZL6-2; Sequence=VSP_057279;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Phosphorylation of Ser-876 correlates with the activation
CC       status of the kinase. Ser-706 is probably phosphorylated by PKC.
CC       Phosphorylation at Ser-244 by CSNK1D and CSNK1E promotes nuclear
CC       localization and substrate targeting. Phosphorylation at Ser-244,
CC       Ser-706 and Ser-710 is required for nuclear localization.
CC       Phosphorylated at Tyr-438 by ABL1 in response to oxidative stress.
CC       {ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027,
CC       ECO:0000269|PubMed:15604256, ECO:0000269|PubMed:17962809}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. PKD subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF36107.1; Type=Frameshift; Positions=604, 606, 738, 744, 755, 758, 833, 854; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF309082; AAK01149.1; -; mRNA.
DR   EMBL; AK074673; BAC11127.1; -; mRNA.
DR   EMBL; AK095884; BAG53158.1; -; mRNA.
DR   EMBL; AC008635; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093503; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KC877745; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL050147; CAB43292.1; -; mRNA.
DR   EMBL; AF151021; AAF36107.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS12689.1; -. [Q9BZL6-1]
DR   CCDS; CCDS59401.1; -. [Q9BZL6-2]
DR   PIR; T08777; T08777.
DR   RefSeq; NP_001073349.1; NM_001079880.1.
DR   RefSeq; NP_001073350.1; NM_001079881.1.
DR   RefSeq; NP_001073351.1; NM_001079882.1.
DR   RefSeq; NP_057541.2; NM_016457.4.
DR   RefSeq; XP_005258773.2; XM_005258716.2.
DR   UniGene; Hs.466987; -.
DR   PDB; 2COA; NMR; -; A=398-509.
DR   PDB; 3BGM; X-ray; 1.60 A; C=526-534.
DR   PDB; 4NNX; X-ray; 2.10 A; C=526-534.
DR   PDB; 4NNY; X-ray; 1.90 A; C=526-534.
DR   PDBsum; 2COA; -.
DR   PDBsum; 3BGM; -.
DR   PDBsum; 4NNX; -.
DR   PDBsum; 4NNY; -.
DR   ProteinModelPortal; Q9BZL6; -.
DR   SMR; Q9BZL6; -.
DR   BioGrid; 117384; 38.
DR   IntAct; Q9BZL6; 35.
DR   MINT; MINT-1179710; -.
DR   STRING; 9606.ENSP00000291281; -.
DR   BindingDB; Q9BZL6; -.
DR   ChEMBL; CHEMBL4900; -.
DR   GuidetoPHARMACOLOGY; 2173; -.
DR   iPTMnet; Q9BZL6; -.
DR   PhosphoSitePlus; Q9BZL6; -.
DR   BioMuta; PRKD2; -.
DR   DMDM; 296434570; -.
DR   EPD; Q9BZL6; -.
DR   MaxQB; Q9BZL6; -.
DR   PaxDb; Q9BZL6; -.
DR   PeptideAtlas; Q9BZL6; -.
DR   PRIDE; Q9BZL6; -.
DR   DNASU; 25865; -.
DR   Ensembl; ENST00000291281; ENSP00000291281; ENSG00000105287.
DR   Ensembl; ENST00000433867; ENSP00000393978; ENSG00000105287.
DR   Ensembl; ENST00000600194; ENSP00000472744; ENSG00000105287.
DR   Ensembl; ENST00000601806; ENSP00000469106; ENSG00000105287.
DR   GeneID; 25865; -.
DR   KEGG; hsa:25865; -.
DR   UCSC; uc002pfi.4; human. [Q9BZL6-1]
DR   CTD; 25865; -.
DR   DisGeNET; 25865; -.
DR   GeneCards; PRKD2; -.
DR   HGNC; HGNC:17293; PRKD2.
DR   HPA; HPA021490; -.
DR   HPA; HPA056727; -.
DR   MIM; 607074; gene.
DR   neXtProt; NX_Q9BZL6; -.
DR   PharmGKB; PA134903505; -.
DR   eggNOG; KOG4236; Eukaryota.
DR   eggNOG; ENOG410XQZ3; LUCA.
DR   HOGENOM; HOG000015135; -.
DR   HOVERGEN; HBG003564; -.
DR   InParanoid; Q9BZL6; -.
DR   KO; K06070; -.
DR   PhylomeDB; Q9BZL6; -.
DR   TreeFam; TF314320; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SignaLink; Q9BZL6; -.
DR   SIGNOR; Q9BZL6; -.
DR   ChiTaRS; PRKD2; human.
DR   EvolutionaryTrace; Q9BZL6; -.
DR   GeneWiki; PRKD2; -.
DR   GenomeRNAi; 25865; -.
DR   PRO; PR:Q9BZL6; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000105287; -.
DR   CleanEx; HS_PKD2; -.
DR   CleanEx; HS_PRKD2; -.
DR   ExpressionAtlas; Q9BZL6; baseline and differential.
DR   Genevisible; Q9BZL6; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004697; F:protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0008219; P:cell death; IMP:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0061154; P:endothelial tube morphogenesis; TAS:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; IGI:BHF-UCL.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB.
DR   GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:1901727; P:positive regulation of histone deacetylase activity; IGI:BHF-UCL.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; ISS:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IMP:UniProtKB.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IGI:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0089700; P:protein kinase D signaling; IGI:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:CACAO.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   CDD; cd00029; C1; 2.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015727; Protein_Kinase_C_mu-related.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22968; PTHR22968; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000552; PKC_mu_nu_D2; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Angiogenesis;
KW   ATP-binding; Cell adhesion; Cell membrane; Complete proteome;
KW   Cytoplasm; Golgi apparatus; Immunity; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    878       Serine/threonine-protein kinase D2.
FT                                /FTId=PRO_0000055716.
FT   DOMAIN      397    509       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      551    807       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     138    188       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     264    314       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     557    565       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    674    674       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     580    580       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     197    197       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     198    198       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     200    200       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     203    203       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     206    206       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     212    212       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BZ03}.
FT   MOD_RES     214    214       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     244    244       Phosphoserine; by CSNK1D and CSNK1E.
FT                                {ECO:0000269|PubMed:17962809}.
FT   MOD_RES     438    438       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:15604256}.
FT   MOD_RES     518    518       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     706    706       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:12058027}.
FT   MOD_RES     710    710       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12058027}.
FT   MOD_RES     717    717       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     876    876       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:11062248,
FT                                ECO:0000269|PubMed:12058027}.
FT   VAR_SEQ       1    157       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057279.
FT   VARIANT     324    324       V -> M (in dbSNP:rs45455991).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042330.
FT   VARIANT     496    496       A -> V (in dbSNP:rs55716765).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042331.
FT   VARIANT     604    604       S -> G (in dbSNP:rs34325043).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042332.
FT   VARIANT     773    773       W -> R (in dbSNP:rs55933311).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042333.
FT   VARIANT     835    835       V -> A (in dbSNP:rs314665).
FT                                {ECO:0000269|PubMed:11042152,
FT                                ECO:0000269|PubMed:11062248,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VAR_061531.
FT   VARIANT     848    848       G -> E (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042334.
FT   VARIANT     870    870       G -> E (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042335.
FT   MUTAGEN     244    244       S->E: Constitutive kinase activity; when
FT                                associated with E-706 and E-710.
FT                                {ECO:0000269|PubMed:23503467}.
FT   MUTAGEN     275    275       P->G: Increase in ability to bind phorbol
FT                                ester, slight increase in ability to bind
FT                                DAG. {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     438    438       Y->F: Loss of phosphorylation.
FT                                {ECO:0000269|PubMed:15604256}.
FT   MUTAGEN     695    695       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:23503467}.
FT   MUTAGEN     706    706       S->E: Constitutive kinase activity; when
FT                                associated with E-710 or with E-244 and
FT                                E-710. {ECO:0000269|PubMed:23503467}.
FT   MUTAGEN     710    710       S->E: Constitutive kinase activity; when
FT                                associated with E-706 or with E-244 and
FT                                E-706. {ECO:0000269|PubMed:23503467}.
FT   CONFLICT    790    790       V -> L (in Ref. 5; AAF36107).
FT                                {ECO:0000305}.
FT   STRAND      399    406       {ECO:0000244|PDB:2COA}.
FT   STRAND      409    411       {ECO:0000244|PDB:2COA}.
FT   STRAND      415    421       {ECO:0000244|PDB:2COA}.
FT   STRAND      423    433       {ECO:0000244|PDB:2COA}.
FT   STRAND      438    442       {ECO:0000244|PDB:2COA}.
FT   TURN        443    445       {ECO:0000244|PDB:2COA}.
FT   STRAND      448    452       {ECO:0000244|PDB:2COA}.
FT   STRAND      456    458       {ECO:0000244|PDB:2COA}.
FT   STRAND      465    470       {ECO:0000244|PDB:2COA}.
FT   STRAND      486    488       {ECO:0000244|PDB:2COA}.
FT   HELIX       495    507       {ECO:0000244|PDB:2COA}.
SQ   SEQUENCE   878 AA;  96750 MW;  8BAB45FB5B1718E7 CRC64;
     MATAPSYPAG LPGSPGPGSP PPPGGLELQS PPPLLPQIPA PGSGVSFHIQ IGLTREFVLL
     PAASELAHVK QLACSIVDQK FPECGFYGLY DKILLFKHDP TSANLLQLVR SSGDIQEGDL
     VEVVLSASAT FEDFQIRPHA LTVHSYRAPA FCDHCGEMLF GLVRQGLKCD GCGLNYHKRC
     AFSIPNNCSG ARKRRLSSTS LASGHSVRLG TSESLPCTAE ELSRSTTELL PRRPPSSSSS
     SSASSYTGRP IELDKMLLSK VKVPHTFLIH SYTRPTVCQA CKKLLKGLFR QGLQCKDCKF
     NCHKRCATRV PNDCLGEALI NGDVPMEEAT DFSEADKSAL MDESEDSGVI PGSHSENALH
     ASEEEEGEGG KAQSSLGYIP LMRVVQSVRH TTRKSSTTLR EGWVVHYSNK DTLRKRHYWR
     LDCKCITLFQ NNTTNRYYKE IPLSEILTVE SAQNFSLVPP GTNPHCFEIV TANATYFVGE
     MPGGTPGGPS GQGAEAARGW ETAIRQALMP VILQDAPSAP GHAPHRQASL SISVSNSQIQ
     ENVDIATVYQ IFPDEVLGSG QFGVVYGGKH RKTGRDVAVK VIDKLRFPTK QESQLRNEVA
     ILQSLRHPGI VNLECMFETP EKVFVVMEKL HGDMLEMILS SEKGRLPERL TKFLITQILV
     ALRHLHFKNI VHCDLKPENV LLASADPFPQ VKLCDFGFAR IIGEKSFRRS VVGTPAYLAP
     EVLLNQGYNR SLDMWSVGVI MYVSLSGTFP FNEDEDINDQ IQNAAFMYPA SPWSHISAGA
     IDLINNLLQV KMRKRYSVDK SLSHPWLQEY QTWLDLRELE GKMGERYITH ESDDVRWEQF
     AAEHPLPGSG LPTDRDLGGA CPPQDHDMQG LAERISVL
//
